Brentuximab vedotin in systemic T-cell lymphoma

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 623-632

  Oki, Yasuhiro ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anaplastic large cell lymphoma; brentuximab vedotin; CD30; MMAE; peripheral T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ANAPLASTIC LYMPHOMA KINASE; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ENZASTAURIN; FLUDARABINE; FORODESINE; FOSTAMATINIB; GEMCITABINE; LENALIDOMIDE; MOGAMULIZUMAB; NELARABINE; PANOBINOSTAT; PENTOSTATIN; PRALATREXATE; PREDNISONE; ROMIDEPSIN; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

AGGRESSIVE NK CELL LEUKEMIA; ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPSTEIN BARR VIRUS INFECTION; FATIGUE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; T CELL LEUKEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, T-CELL; PROGNOSIS;

EID: 84859620765     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.670216     Document Type: Review

References (53)

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-30 Extremely important study 'International T-cell Lymphoma Project'.
2. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117(12):3402-8
3. Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117(25):6756-67 Excellent review on PTCL.
4. Organization WH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC Press; Lyon, France: 2008
5. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96(13):4319-27
6. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001;61(5):2194-9 (Pubitemid 32692047)
7. Zhang Q, Raghunath PN, Xue L, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002;168(1):466-74 (Pubitemid 34014150)
8. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004;103(4):1464-71 (Pubitemid 38168663)
9. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007;67(9):4278-86 (Pubitemid 46815075)
10. Hsu FY, Johnston PB, Burke KA, Zhao Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 2006;66(18):9002-8 (Pubitemid 44521118)
11. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111(12):5496-504
12. Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA). ASH Annu Meeting Abstr 2010;116(21):abstract322
13. Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 2010;92(5):697-701
14. Chen AI, McMillan A, Negrin RS, et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanfordexperience. Biol Blood Marrow Transplant 2008; 14(7):741-7 (Pubitemid 351784371)
15. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27(1):106-13
16. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9
17. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-34
18. Coiffier B, Pro B, Prince HM, et al. Analysis of patients with common peripheral T-Cell lymphoma subtypes from a phase 2 study of romidepsin in relapsed or refractory peripheral T-Cell lymphoma. ASH Annu Meeting Abstr 2011;118(21):abstract591
19. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007;136(3):439-47 (Pubitemid 46046302)
20. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103(8):2920-4 (Pubitemid 38451660)
21. Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90(5):702-3 (Pubitemid 40780898)
22. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96(13):4307-12
23. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997;11(21):2810-21 (Pubitemid 27481682)
24. Hecht TT, Longo DL, Cossman J, et al. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol 1985;134(6):4231-6
25. Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997;15(11):3355-62 (Pubitemid 27485855)
26. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10(6):457-70 (Pubitemid 28564375)
27. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003;10(4):267-71 (Pubitemid 36724349)
28. Segal GH, Kjeldsberg CR, Smith GP, Perkins SL. CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am J Clin Pathol 1994;102(3):292-8 (Pubitemid 24330987)
29. Elgin J, Phillips JG, Reddy VV, et al. Hodgkin's and non-Hodgkin's lymphoma: spectrum of morphologic and immunophenotypic overlap. Ann Diagn Pathol 1999;3(5):263-75
30. Eow GI, Kim LH, Peh SC. The pattern of CD15, CD30 and Bcl-2 expression in diffuse large B-cell lymphoma. Med J Malaysia 2006;61(4):416-21
31. Gardner LJ, Polski JM, Evans HL, et al. CD30 expression in follicular lymphoma. Arch Pathol Lab Med 2001;125(8):1036-41 (Pubitemid 32738282)
32. Kolonic SO, Dzebro S, Kusec R, et al. Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics. Int J Hematol 2006;83(4):331-6 (Pubitemid 43810119)
33. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995;89(4):780-9
34. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999;112(2):241-7 (Pubitemid 30212541)
35. Asano N, Yamamoto K, Tamaru J, et al. Age-related Epstein-Barr virus (EBV)- associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009;113(12):2629-36
36. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13(1):140-9 (Pubitemid 34436738)
37. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24(16):2472-9 (Pubitemid 46630624)
38. Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol 2004;12(4):375-87
39. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113(17):3931-7
40. Takeshita M, Nakamura S, Kikuma K, et al. Pathological and immunohistological findings and genetic aberrations of intestinal enteropathy-associated T cell lymphoma in Japan. Histopathology 2011;58(3):395-407
41. Walsh SV, Egan LJ, Connolly CE, et al. Enteropathy-associated T-cell lymphoma in the West of Ireland: low-frequency of Epstein-Barr virus in these tumors. Mod Pathol 1995;8(7):753-7
42. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95(12):3653-61 (Pubitemid 30412833)
43. Boulland ML, Wechsler J, Bagot M, et al. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000;36(2):136-44 (Pubitemid 30113975)
44. Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006;126(3):575-83 (Pubitemid 43255644)
45. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX- 060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25(19):2764-9 (Pubitemid 47123185)
46. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009;15(19):6217-24
47. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti- CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146(2):171-9
48. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102(4):1458-65 The first preclinical report of anti-CD30 antibody conjugated with MMAE.
49. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14(4):529-37
50. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21 The important Phase I clinical report of brentuximab vedotin.
51. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A Phase 1 Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 2012;18(1):248-55
52. Pro B, Advani R, Brice P, et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 2011;29:abstract 8032
53. Bartlett N, Grove LE, Kennedy DA, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series. J Clin Oncol 2010;28(15s):abstract 8062